e-Therapeutics plc (LON:ETX) insider Trevor Mervyn Jones bought 59,400 shares of e-Therapeutics plc stock in a transaction on Friday, May 12th. The shares were bought at an average cost of GBX 8 ($0.10) per share, with a total value of £4,752 ($6,011.39).
e-Therapeutics plc (ETX) traded up 11.236% on Friday, reaching GBX 12.375. The company’s stock had a trading volume of 2,360,038 shares. The stock has a 50-day moving average of GBX 8.44 and a 200-day moving average of GBX 8.37. e-Therapeutics plc has a one year low of GBX 6.00 and a one year high of GBX 14.00. The stock’s market cap is GBX 33.22 million.
TRADEMARK VIOLATION WARNING: “Insider Buying: e-Therapeutics plc (ETX) Insider Purchases 59,400 Shares of Stock” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/06/16/trevor-mervyn-jones-purchases-59400-shares-of-e-therapeutics-plc-etx-stock-updated-updated.html.
About e-Therapeutics plc
e-Therapeutics plc is a United Kingdom-based drug discovery and development company. The Company’s discovery platform is based on the network of pharmacology and chemical biology. The Company operates in the business segment of drug discovery and development. The Company applies its platform to the discovery of new drug candidates.
Receive News & Ratings for e-Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.